Portal de Periódicos da CAPES

Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients

2008; Oxford University Press; Volume: 46; Issue: 1 Linguagem: Inglês

10.1086/523590

1537-6591

Óscar Len, Joan Gavaldà, José María Aguado, Núria Borrell, Carlos Cervera, José Miguel Cisneros, Valentín Cuervas‐Mons, Mercè Gurguí, Pilar Martín‐Dávila, Miguel Montejo, Patricia Muñóz, Germán Bou, Jordi Carratalà, Julián Torre‐Cisneros, Albert Pahissa,

Neurological Complications and Syndromes

Background. Cytomegalovirus (CMV) infection causes morbidity in solid organ transplant (SOT) recipients, either by direct injury or in association with chronic allograft rejection or other opportunistic infections. Ganciclovir is the treatment of choice, but this agent requires intravenous administration, which affects its feasibility for long‐term use. Valganciclovir, which has an oral bioavailability of 60%, has proven to be useful for prophylaxis of CMV infection in high‐risk SOT recipients and for treating retinitis in persons with acquired immunodeficiency syndrome.